Rani Therapeutics Q2 net loss $11.2M, cash at $10.2M; collaboration with Chugai announced

Rani Therapeutics Holdings, Inc.

2025-Q2 EPS reported -$0.40 revenue$172,000

Net loss of $11.2M for Q2 2025 vs $13.4M in Q2 2024; includes $3.3M stock-based compensation.
Cash, equivalents and marketable securities fell to $10.2M as of June 30, 2025 from $27.6M at Dec 31, 2024.
Entered research collaboration with Chugai for two undisclosed molecules; bioequivalence to subcutaneous delivery confirmed.
Warrant inducement transaction yielded $4.3M gross proceeds; registered direct offering raised $3.0M.
Phase 1 trial of oral GLP-1/GLP-2 agonist RT-114 for obesity expected to start H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.